目的 探討沙庫(kù)巴曲纈沙坦鈉聯(lián)合拉西地平治療高血壓的臨床療效。方法 選取2022年11月—2024年5月鄭州人民醫(yī)院心血管內(nèi)科收治的126例高血壓患者，依據(jù)隨機(jī)數(shù)字法現(xiàn)將入組高血壓患者分為對(duì)照組63例和治療組63例。對(duì)照組患者給予口服拉西地平分散片，4 mg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上給予口服沙庫(kù)巴曲纈沙坦鈉片，100 mg/次，2次/d。兩組用藥42 d觀察治療情況。觀察兩組臨床療效和臨床癥狀緩解時(shí)間，比較兩組治療前后收縮壓、舒張壓、血清血管內(nèi)皮因子、血清炎性因子水平的變化。結(jié)果 用藥42 d后，治療組總有效率96.83%，顯著高于對(duì)照組的84.13%（P＜0.05）。用藥42 d后，治療組患者頭暈、耳鳴、頭痛、心律失常癥狀緩解時(shí)間顯著短于對(duì)照組（P＜0.05）。治療后，兩組患者內(nèi)皮素-1（ET-1）、血管內(nèi)皮生長(zhǎng)因子（VEGF）水平顯著降低，而一氧化氮（NO）、降鈣素基因相關(guān)肽（CGRP）水平升高（P＜0.05）；治療后，治療組ET-1、VEGF水平低于對(duì)照組，NO、CGRP高于對(duì)照組（P＜0.05）。治療后，兩組可溶性生長(zhǎng)刺激表達(dá)基因2蛋白（sST2）、白細(xì)胞介素-8（IL-8）、轉(zhuǎn)化生長(zhǎng)因子-β1（TGF-β1）、腫瘤壞死因子-α（TNF-α）水平均顯著降低（P＜0.05）；治療后，與對(duì)照組對(duì)比，治療組sST2、IL-8、TNF-α、TGF-β1水平均較低（P＜0.05）。結(jié)論 沙庫(kù)巴曲纈沙坦鈉聯(lián)合拉西地平治療高血壓療效顯著，可明顯緩解高血壓癥狀，并能調(diào)節(jié)血管內(nèi)皮因子功能，減弱機(jī)體炎性反應(yīng)，值得借鑒與應(yīng)用。

Objective To investigate the therapeutic effect of lacidipine combined with sacubitril valsartan sodium in treatment of hypertension. Methods A total of 126 hypertensive patients admitted to the cardiovascular Department of Zhengzhou People's Hospital from November 2022 to May 2024 were selected and divided into control group (63 cases) and treatment group (63 cases) according to random number method. Patients in control group were po administered with Lacidipine Dispersible Tablets, 4 mg/time, once daily. Patients in treatment group were po administered with Sacubitril Valsartan Sodium Tablets on the basis of control group, 100 mg/time, twice daily. The two groups were treated for 42 d to observe the treatment. The clinical effects and duration of relief of clinical symptoms of two groups were observed, and the changes of systolic blood pressure, diastolic blood pressure, serum vascular endothelial factors and serum inflammatory factors before and after treatment were compared. Results After 42 d of treatment, the total effective rate of treatment group was 96.83%, which was significantly higher than that of control group (84.13%, P < 0.05). After 42 d of medication, the relief time of dizziness, tinnitus, headache and arrhythmia in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, the levels of ET-1 and VEGF were significantly decreased, but the levels of NO and CGRP were increased in 2 groups (P < 0.05). After treatment, the levels of ET-1 and VEGF in treatment group were lower than those in control group, but the levels of NO and CGRP were higher than those in control group (P < 0.05). After treatment, the levels of sST2, IL-8, TGF-β1, and TNF-α were significantly decreased in both groups (P < 0.05). After treatment, the levels of sST2, IL-8, TNF-α and TGF-β1 in treatment group were lower than those in control group (P < 0.05). Conclusion Lacidipine combined with sacubitril valsartan sodium is effective in treatment of hypertension, and can significantly relieve the symptoms of hypertension, regulate the function of vascular endothelial factors, and weaken the inflammatory response of the body, which is worth learning and application.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20220803）